Lack of Durable Responses in Current Treatment of mCRC

Initial Management of Metastatic CRC in 2019Подробнее

Deciding Second-Line Treatment for mCRCПодробнее

Maintenance Therapy for mCRCПодробнее

Case 2: Maintenance Therapy in mCRCПодробнее

TACT-D: a randomized study evaluating tailoring of mCRC therapy using ctDNAПодробнее

Key limitations of current treatment options for patients with MSS-CRCПодробнее

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRCПодробнее

Achieving a Durable Response With Regorafenib in mCRCПодробнее

Long term response in mCRCПодробнее

IMblaze370 Trial in MSS mCRCПодробнее

Using Immunotherapy for the Treatment of mCRCПодробнее

Frontline Therapy for mCRCПодробнее

2022 West Oncology Conference | Gastrointestinal Cancers | Colorectal SessionПодробнее

Newly Diagnosed mCRC Treatment GoalsПодробнее

Choices for Upfront Therapy for mCRCПодробнее

Treatment for RAS-mutated mCRCПодробнее

Overcoming Acquired Resistance Mechanisms in BRAF+ mCRCПодробнее

The Treatment Goals of mCRCПодробнее

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRCПодробнее